단일 상급종합병원에서 PNAC 소아 환자 치료 현황
Treatment Status of Parenteral Nutrition-Associated Cholestasis in Pediatric Patients at a Single Tertiary Hospital
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Parenteral nutrition-associated cholestasis (PNAC) may occur in neonates and pediatric patients receiving long-term parenteral nutrition (PN). This study aimed to provide a real-world data analysis of treatment status of PNAC patients under 12 years in clinical practice. Methods : A retrospective analysis was conducted from January 2015 to December 2022 on pediatric patients diagnosed with PNAC aged less than 12 years who were admitted to the hospital. These patients received parenteral nutrition for two weeks or more. Implementa tion rates of various treatment methods, changes in liver function, nutrition-related test results after initiation of treatment, and duration of treatment were examined. Results : This study included 38 patients (24 neonates, 10 infants, and 4 children). The primary diagnosis was prematurity, observed in 19 (50.0%) cases. Comorbidities included patent ductus arteriosus (25 cases, 65.8%) and sepsis (19 cases, 50.0%). Various meth ods were employed for treating PNAC. 37 (97.4%) patients received ursodeoxycholic acid (UDCA). 24 (63.2%) patients had total caloric and nutritional compositions of PN changed. 18 (47.4%) patients had PN discontinued. 16 (42.1%) patients received EN. 7 (18.4%) pa tients received cyclic PN and 2 (5.3%) patients received 100% fish oil lipid emulsions. On average, each patient underwent 2.9 different treatment methods simultaneously. Direct bilirubin level at the time of PNAC diagnosis was 3.7 mg/dL. After 7 weeks of treatment, 20 (52.6%) patients showed recovery from PNAC. The median duration of PNAC treatment was 29.0 days (range, 5.0-200.0 months). Conclusion : This study examined implementation rates of various treatment methods for pediatric PNAC patients and investigated their effects on liver function and changes in nu tritional supply. Findings of this study suggest that future research addressing limitations of this study may provide meaningful treatment approaches for PNAC.
Abstract
Background : Parenteral nutrition-associated cholestasis (PNAC) may occur in neonates and pediatric patients receiving long-term parenteral nutrition (PN). This study aimed to provide a real-world data analysis of treatment status of PNAC patients under 12 years in clinical practice. Methods : A retrospective analysis was conducted from January 2015 to December 2022 on pediatric patients diagnosed with PNAC aged less than 12 years who were admitted to the hospital. These patients received parenteral nutrition for two weeks or more. Implementa tion rates of various treatment methods, changes in liver function, nutrition-related test results after initiation of treatment, and duration of treatment were examined. Results : This study included 38 patients (24 neonates, 10 infants, and 4 children). The primary diagnosis was prematurity, observed in 19 (50.0%) cases. Comorbidities included patent ductus arteriosus (25 cases, 65.8%) and sepsis (19 cases, 50.0%). Various meth ods were employed for treating PNAC. 37 (97.4%) patients received ursodeoxycholic acid (UDCA). 24 (63.2%) patients had total caloric and nutritional compositions of PN changed. 18 (47.4%) patients had PN discontinued. 16 (42.1%) patients received EN. 7 (18.4%) pa tients received cyclic PN and 2 (5.3%) patients received 100% fish oil lipid emulsions. On average, each patient underwent 2.9 different treatment methods simultaneously. Direct bilirubin level at the time of PNAC diagnosis was 3.7 mg/dL. After 7 weeks of treatment, 20 (52.6%) patients showed recovery from PNAC. The median duration of PNAC treatment was 29.0 days (range, 5.0-200.0 months). Conclusion : This study examined implementation rates of various treatment methods for pediatric PNAC patients and investigated their effects on liver function and changes in nu tritional supply. Findings of this study suggest that future research addressing limitations of this study may provide meaningful treatment approaches for PNAC.
참고문헌 (34)
- Liu SY, "Ursodeoxycholic acid prevention on cholestasis associated with total parenteral nutrition in preterm infants : a randomized trial", World J Pediatr, 18(2), pp.100~108 (2022)
- Drongowski RA, "An analysis of factors contributing to the development of total parenteral nutrition-induced cholestasis", JPEN J Parenter Enteral Nutr, 13(6), pp.586~589 (1989)
- Orso G, "Pediatric parenteral nutrition-associated liver disease and cholestasis : Novel advances in pathomechanisms-based prevention and treatment", Dig Liver Dis, 48(3), pp.215~222 (2016)
- Nehra D, "The prevention and treatment of intestinal failure-associated liver disease in neonates and children", Surg Clin North Am, 91(3), pp.543~563 (2011)
- Jin Hong Lim, "Surgical Metabolism and Nutrition 8" (2017)
- Seoul National University Children’s Hospital, Nutrition Support Team, "Pediatric nutrition support" (2021), Daehan Medical Book
- Diamond IR, "Novel lipid-based approaches to pediatric intestinal failure-associated liver disease", Arch Pediatr Adolesc Med, 166(5), pp.473~478 (2012)
- Guglielmi FW, "Cholestasis induced by total parenteral nutrition", Clin Liver Dis, 12(1), pp.97~110 (2008)
- Mihatsch WA, "ESPGHAN", ESPEN, CSPEN guidelines on pediatric parenteral nutrition, pp.Clin Nutr, 2018[DOI]
- Wales PW, "A. S. P. E. N. clinical guidelines : support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease", JPEN J Parenter Enteral Nutr, 38(5), pp.538~557 (2014)
- Kim AY, "Parenteral Nutrition-Associated Cholestasis in Very Low Birth Weight Infants : A Single Center Experience", Pediatric gastroenterology, hepatology & nutrition, 19(1), pp.61~70 (2016)
- Park KP, "Total Parenteral Nutrition-associated Cholestasis in Premature Infants", Clinical and Experimental Pediatrics(CEP), 46(1), pp.17~23 (2003)
- Lee SM, "High incidence of rickets in extremely low birth weight infants with severe parenteral nutrition-associated cholestasis and bronchopulmonary dysplasia", J Korean Med Sci, 27(12), pp.1552~1555 (2012)
- ICH Topic E11 Clinical Investigation of Medicinal Products in the Paediatric Population, "European Medicines Agency", European Medicines Agency, ~ (2001)
- Singer P, "ESPEN guideline on clinical nutrition in the intensive care unit", Clin Nutr, 38(1), pp.48~79 (2019)
- Chen CY, "Ursodeoxycholic acid(UDCA)therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis", J Pediatr, 145(3), pp.317~321 (2004)
- Christensen RD, "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease", J Perinatol, 27(5), pp.284~290 (2007)
- Wang YS, "Analysis of risk factors for parenteral nutrition-associated cholestasis in preterm infants : a multicenter observational study", BMC Pediatr, 23(1), pp.250~ (2023)
- Rangel SJ, "Parenteral nutrition-associated cholestasis : an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review", J Pediatr Surg, 47(1), pp.225~240 (2012)
- YA Kim, "Understanding and application of liver function test", The Korean Journal of Medicine, 76(2), pp.163~168 (2009)
- SY Han, "Evaluation on the Time to Start Parenteral Nutrition in Pediatric Intensive Care Unit", J. Kor. Soc. Health-syst. Pharm, 36(3), pp.353~365 (2019)
- Grijalva J, "Neonatal liver physiology", Semin Pediatr Surg, 22(4), pp.185~189 (2013)
- Lloyd DA, "Chronic biochemical cholestasis in patients receiving home parenteral nutrition : prevalence and predisposing factors", Aliment Pharmacol Ther, 27(7), pp.552~560 (2008)
- Vileisis RA, "Prospective controlled study of parenteral nutrition-associated cholestatic jaundice : effect of protein intake", J Pediatr, 96(5), pp.893~897 (1980)
- 장동경, "내과 입원환자의영양관리 가이드북" (2022), 대한장연구학회
- Mehta NM, "Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient:Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition", JPEN J Parenter Enteral Nutr, 41(5), pp.706~742 (2017)
- Stout SM, "Metabolic effects of cyclic parenteral nutrition infusion in adults and children", Nutr Clin Pract, 25(3), pp.277~281 (2010)
- Cowett RM, "The role of hepatic control of glucose homeostasis in the etiology of neonatal hypo-and hyperglycemia", Semin Perinatol, 3(4), pp.327~340 (1979)
- El Kasmi KC, "Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease", Sci Transl Med, 5(206), pp.206ra137~ (2013)
- Carter BA, "Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR", Pediatr Res, 62(3), pp.301~306 (2007)
- Carlson SE, "Essentiality of omega 3 fatty acids in growth and development of infants", World Rev Nutr Diet, 66, pp.74~86 (1991)
- Nehra D, "Provision of a soy-based intravenous lipid emulsion at 1 g", kg, JPEN J Parenter Enteral Nutr, pp.2013, 37(4)[DOI]
- Strang BJ, "Improvement in Parenteral Nutrition-Associated Cholestasis With the Use of Omegaven in an Infant With Short Bowel Syndrome", Nutr Clin Pract, 31(5), pp.647~653 (2016)
- Spencer AU, "Parenteral nutrition-associated cholestasis in neonates : multivariate analysis of the potential protective effect of taurine", JPEN J Parenter Enteral Nutr, 29(5), pp.337~343 (2005)